Amer Oriental Plans To Buy Changchun Xinan Pharm For $30M (China)
This article was originally published in PharmAsia News
American Oriental Bioengineering Inc. has signed a letter of intent to acquire Changchun Xinan Pharmaceutical Group Co., a privately owned plant-based pharmaceutical company, for up to about $30 million. American Oriental, which is based in China, said it has 90 days to enter into a definitive purchase agreement and close the transaction. American Oriental says the transaction is consistent with its acquisition strategy to acquire companies that are accretive to its operations within one year of closing. (Click here for more - May Require Paid Subscription
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.